Rodrigo Lázaro-Gorines

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity

L. Álvarez-Vallina, B. Blanco, K. Howard, 2022, iScience.

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

L. Álvarez-Vallina, B. Blanco, J. Bonet, 2023, Oncoimmunology.

Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2

R. Godoy-Ruiz, K. Adipietro, L. Álvarez-Vallina, 2023, Advanced science.